骨髓基质体外功能与山莨菪碱治疗再生障碍性贫血的相关性研究

以培养3周的骨髓基质细胞为滋养层（SL）进行正常人骨髓细胞CFU－GM培养，以无基质层的CFU－GM为对照，评定骨髓基质功能，观察再生障碍性贫血患骨髓基质功能与山莨菪碱疗效关系。结果显示，培养3周的正常骨髓SL上CFU－GM产率明显高于无基质层对照；10例再生障碍性贫血患中4例培养3周的骨髓SL上CFU－GM产率为对照的80％以下，余6例为对照的80％以上。低于80％的4例，山莨菪碱治疗后均取得一定疗效，其中2例复查基质功能，基质层上CFU－GM产率分别由为对照的38．66％和39．71增至168．8％和249．2％，而高于80％的6例，仅1例有效。结论：正常骨髓基质融合层对粒系祖细胞生长具有明显支持作用；基质功能障碍所致再生障碍性贫血经山莨菪碱治疗后可改善基质功能，达到治疗目的。

Correlation of Bone Marrow Stromal Function In Vitro with Effecacy of Anisodamine Therapy for Aplastic Anemia

To observe normal bone marrow stromal function for supporting hematopoiesis and realize the correlation of bone marrow stromal function in patients with aplastic anemia (AA) and anisodamine therapy, normal human marrow CFU GM was assayed on bone marrow stromal layer (SL) formed on week 3 culture, and the CFU GM without SL as a control(100%). Results showed that the production of CFU GM on the normal SL was significantly higher than that of the control. The production of CFU GM on the SL of 4 AA patients, who responded to anisodamine, was <80% of the control, and when 2 of them were reexamined for stromal function after treatment, the number of CFU GM on SL rose up to 168 8% and 249 2% from 38 7% and 39 7% of the control respectively. While in the rest 6 patients, the number of CFU GM was >80% of the control, only one patient was improved by anisodamine therapy. So, normal bone marrow stromal layer can obviously support the growth of granulocyte/marcrophage progenitor cells. Anisodamine therapy could be an effective agents for aplastic anemia with stromal dysfunction.